Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

636715.pdf (834.36 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2013-12

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/66170

Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.2174/18715273113129990115

Resum

Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and glial cells modulating the effects of glutamatergic neurotransmission. The pharmacological manipulation of these receptors has been postulated to be valuable in the management of some neurological disorders. Accordingly, the targeting of mGlu5 receptors as a therapeutic approach for Parkinson's disease (PD) has been proposed, especially to manage the adverse symptoms associated to chronic treatment with classical PD drugs. Thus, the specific pharmacological blocking of mGlu5 receptors constitutes one of the most attractive non-dopaminergic-based strategies for PD management in general and for the L-DOPA-induced diskynesia (LID) in particular. Overall, we provide here an update of the current state of the art of these mGlu5 receptor-based approaches that are under clinical study as agents devoted to alleviate PD symptoms.

Matèries

Malaltia de Parkinson, Receptors de neurotransmissors, Neurofarmacologia, Assaigs clínics

Matèries (anglès)

Parkinson's disease, Neurotransmitter receptors, Neuropharmacology, Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)

Citació

VALLANO FERRAZ, Antonio, et al. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials. CNS & Neurological Disorders-Drug Targets. 2013. Vol. 12, num. 8, pags. 1128-1142. ISSN 1871-5273. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/66170

Exportar metadades

JSON - METS

Compartir registre